Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer.
Yihong WangKamaljeet SinghDon DizonTeresa GravesAli AminEvgeny YakirevichPublished in: Breast cancer research and treatment (2021)
There is significant heterogeneity in response to the NACH regimens in HER2 + cases. Our findings indicate that HER2 IHC score and ER expression determine NACH response in HER2 + BC. We recommend considering HER2 protein expression and ISH value to better select patients and assess the response for HER2-targeted therapy.
Keyphrases
- neoadjuvant chemotherapy
- end stage renal disease
- ejection fraction
- locally advanced
- newly diagnosed
- poor prognosis
- lymph node
- chronic kidney disease
- prognostic factors
- sentinel lymph node
- single cell
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes
- early stage
- estrogen receptor
- endoplasmic reticulum
- patient reported
- long non coding rna
- breast cancer risk